INDP · Indaptus Therapeutics Inc
United States · RS rating 96 · As of 2026-11-03
| Price | 3.24 USD |
|---|---|
| 1-day change | -7.4% |
| RS rating (overall / 1M / 3M / 12M) | 96 / 96 / 97 / 51 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 39 / 38 / 55 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +91.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +31.8% |
| Market cap (USD) | $7.1M |